BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

366 related articles for article (PubMed ID: 31286691)

  • 1. The systemic activin response to pancreatic cancer: implications for effective cancer cachexia therapy.
    Zhong X; Pons M; Poirier C; Jiang Y; Liu J; Sandusky GE; Shahda S; Nakeeb A; Schmidt CM; House MG; Ceppa EP; Zyromski NJ; Liu Y; Jiang G; Couch ME; Koniaris LG; Zimmers TA
    J Cachexia Sarcopenia Muscle; 2019 Oct; 10(5):1083-1101. PubMed ID: 31286691
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sex specificity of pancreatic cancer cachexia phenotypes, mechanisms, and treatment in mice and humans: role of Activin.
    Zhong X; Narasimhan A; Silverman LM; Young AR; Shahda S; Liu S; Wan J; Liu Y; Koniaris LG; Zimmers TA
    J Cachexia Sarcopenia Muscle; 2022 Aug; 13(4):2146-2161. PubMed ID: 35510530
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elevated expression of activins promotes muscle wasting and cachexia.
    Chen JL; Walton KL; Winbanks CE; Murphy KT; Thomson RE; Makanji Y; Qian H; Lynch GS; Harrison CA; Gregorevic P
    FASEB J; 2014 Apr; 28(4):1711-23. PubMed ID: 24378873
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Visceral adipose tissue remodeling in pancreatic ductal adenocarcinoma cachexia: the role of activin A signaling.
    Xu PC; You M; Yu SY; Luan Y; Eldani M; Caffrey TC; Grandgenett PM; O'Connell KA; Shukla SK; Kattamuri C; Hollingsworth MA; Singh PK; Thompson TB; Chung S; Kim SY
    Sci Rep; 2022 Jan; 12(1):1659. PubMed ID: 35102236
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pro-cachectic factors link experimental and human chronic kidney disease to skeletal muscle wasting programs.
    Solagna F; Tezze C; Lindenmeyer MT; Lu S; Wu G; Liu S; Zhao Y; Mitchell R; Meyer C; Omairi S; Kilic T; Paolini A; Ritvos O; Pasternack A; Matsakas A; Kylies D; Wiesch JSZ; Turner JE; Wanner N; Nair V; Eichinger F; Menon R; Martin IV; Klinkhammer BM; Hoxha E; Cohen CD; Tharaux PL; Boor P; Ostendorf T; Kretzler M; Sandri M; Kretz O; Puelles VG; Patel K; Huber TB
    J Clin Invest; 2021 Jun; 131(11):. PubMed ID: 34060483
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of stromal activin A in human pancreatic cancer and metastasis in mice.
    Mancinelli G; Torres C; Krett N; Bauer J; Castellanos K; McKinney R; Dawson D; Guzman G; Hwang R; Grimaldo S; Grippo P; Jung B
    Sci Rep; 2021 Apr; 11(1):7986. PubMed ID: 33846512
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Myostatin is a novel tumoral factor that induces cancer cachexia.
    Lokireddy S; Wijesoma IW; Bonala S; Wei M; Sze SK; McFarlane C; Kambadur R; Sharma M
    Biochem J; 2012 Aug; 446(1):23-36. PubMed ID: 22621320
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ACVR2B antagonism as a countermeasure to multi-organ perturbations in metastatic colorectal cancer cachexia.
    Huot JR; Pin F; Narasimhan A; Novinger LJ; Keith AS; Zimmers TA; Willis MS; Bonetto A
    J Cachexia Sarcopenia Muscle; 2020 Dec; 11(6):1779-1798. PubMed ID: 33200567
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum insulin-like growth factor binding protein 2 levels as biomarker for pancreatic ductal adenocarcinoma-associated malnutrition and muscle wasting.
    Dong J; Yu J; Li Z; Gao S; Wang H; Yang S; Wu L; Lan C; Zhao T; Gao C; Liu Z; Wang X; Hao J
    J Cachexia Sarcopenia Muscle; 2021 Jun; 12(3):704-716. PubMed ID: 33763996
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor-derived IL-6 and trans-signaling among tumor, fat, and muscle mediate pancreatic cancer cachexia.
    Rupert JE; Narasimhan A; Jengelley DHA; Jiang Y; Liu J; Au E; Silverman LM; Sandusky G; Bonetto A; Cao S; Lu X; O'Connell TM; Liu Y; Koniaris LG; Zimmers TA
    J Exp Med; 2021 Jun; 218(6):. PubMed ID: 33851955
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activin signal promotes cancer progression and is involved in cachexia in a subset of pancreatic cancer.
    Togashi Y; Kogita A; Sakamoto H; Hayashi H; Terashima M; de Velasco MA; Sakai K; Fujita Y; Tomida S; Kitano M; Okuno K; Kudo M; Nishio K
    Cancer Lett; 2015 Jan; 356(2 Pt B):819-27. PubMed ID: 25449777
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute inhibition of myostatin-family proteins preserves skeletal muscle in mouse models of cancer cachexia.
    Benny Klimek ME; Aydogdu T; Link MJ; Pons M; Koniaris LG; Zimmers TA
    Biochem Biophys Res Commun; 2010 Jan; 391(3):1548-54. PubMed ID: 20036643
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevention of chemotherapy-induced cachexia by ACVR2B ligand blocking has different effects on heart and skeletal muscle.
    Hulmi JJ; Nissinen TA; Räsänen M; Degerman J; Lautaoja JH; Hemanthakumar KA; Backman JT; Ritvos O; Silvennoinen M; Kivelä R
    J Cachexia Sarcopenia Muscle; 2018 Apr; 9(2):417-432. PubMed ID: 29230965
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Growth of ovarian cancer xenografts causes loss of muscle and bone mass: a new model for the study of cancer cachexia.
    Pin F; Barreto R; Kitase Y; Mitra S; Erne CE; Novinger LJ; Zimmers TA; Couch ME; Bonewald LF; Bonetto A
    J Cachexia Sarcopenia Muscle; 2018 Aug; 9(4):685-700. PubMed ID: 30009406
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activin A induces skeletal muscle catabolism via p38β mitogen-activated protein kinase.
    Ding H; Zhang G; Sin KW; Liu Z; Lin RK; Li M; Li YP
    J Cachexia Sarcopenia Muscle; 2017 Apr; 8(2):202-212. PubMed ID: 27897407
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systemic blockade of ACVR2B ligands attenuates muscle wasting in ischemic heart failure without compromising cardiac function.
    Szabó Z; Vainio L; Lin R; Swan J; Hulmi JJ; Rahtu-Korpela L; Serpi R; Laitinen M; Pasternack A; Ritvos O; Kerkelä R; Magga J
    FASEB J; 2020 Aug; 34(8):9911-9924. PubMed ID: 32427381
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Muscle NAD
    Hulmi JJ; Penna F; Pöllänen N; Nissinen TA; Hentilä J; Euro L; Lautaoja JH; Ballarò R; Soliymani R; Baumann M; Ritvos O; Pirinen E; Lalowski M
    Mol Metab; 2020 Nov; 41():101046. PubMed ID: 32599075
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MEF2c-Dependent Downregulation of Myocilin Mediates Cancer-Induced Muscle Wasting and Associates with Cachexia in Patients with Cancer.
    Judge SM; Deyhle MR; Neyroud D; Nosacka RL; D'Lugos AC; Cameron ME; Vohra RS; Smuder AJ; Roberts BM; Callaway CS; Underwood PW; Chrzanowski SM; Batra A; Murphy ME; Heaven JD; Walter GA; Trevino JG; Judge AR
    Cancer Res; 2020 May; 80(9):1861-1874. PubMed ID: 32132110
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Autocrine activin A signalling in ovarian cancer cells regulates secretion of interleukin 6, autophagy, and cachexia.
    Pettersen K; Andersen S; van der Veen A; Nonstad U; Hatakeyama S; Lambert C; Lach-Trifilieff E; Moestue S; Kim J; Grønberg BH; Schilb A; Jacobi C; Bjørkøy G
    J Cachexia Sarcopenia Muscle; 2020 Feb; 11(1):195-207. PubMed ID: 31436048
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treating cachexia using soluble ACVR2B improves survival, alters mTOR localization, and attenuates liver and spleen responses.
    J Cachexia Sarcopenia Muscle; ; . PubMed ID: 29722201
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.